The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,241.00
Bid: 2,240.00
Ask: 2,242.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.089%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2,241.00
HLMA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

22 Sep 2021 07:00

RNS Number : 5177M
Halma PLC
22 September 2021
 

Trading update

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner and healthier future, today releases its scheduled trading update, for the period from 1 April 2021 to date.

Strong progress in the first half and improved guidance for the full year

Halma has made strong progress in the first half of the financial year, and the Group's financial performance has been ahead of the Board's expectations, with revenue growth and return on sales exceeding expectations and historic levels. Order intake has been ahead of both revenue this year and of order intake for the same period last year. This performance reflects the benefits of the long-term growth drivers in our markets, the breadth of our portfolio, and the agility of our business model which has enabled our companies to respond rapidly to changing market conditions.

We expect to report strong organic constant currency revenue and profit growth for the first half of the year, with profitability benefitting from a slower-than-expected return of variable overhead costs as restrictions due to the COVID pandemic have eased. This performance compares to a weaker comparative period in the first half of the 2020/21 financial year when we saw the largest impacts from the pandemic.

We expect more typical rates of revenue growth and return on sales in the second half of the year, with the latter more in line with historic levels as variable overhead costs gradually return. Although we expect to see continued impact on revenue, costs and working capital from increased supply chain, logistics and labour market disruption, we currently expect Adjusted profit before tax for the full year to be slightly ahead of our previous guidance (see Notes 1 and 2). Therefore, our results for the full year are expected to be more weighted to the first half than in previous years.

All sectors and major geographic regions delivered strong organic constant currency growth

The Safety and Environmental & Analysis sectors reported the strongest organic revenue and profit growth in the year to date, with many companies experiencing significant increases in demand because of a rebound in customer activity as the effects of the COVID pandemic moderated.

The Medical sector also delivered strong growth, with revenue benefiting from a recovery in demand for most products and services related to elective healthcare procedures, which offset declining demand for products and services directly related to COVID diagnosis or treatment.

The Safety and Environmental & Analysis sectors saw a small negative impact from recent disposals, net of acquisitions, while the Medical sector benefited from recent acquisitions.

There was widespread growth geographically, with double-digit percentage organic constant currency revenue increases in all major regions. There was very strong organic constant currency growth in the UK and Asia Pacific, while the USA and Mainland Europe also grew strongly.

The strength of Sterling is having a negative currency translation effect on the Group's results (see Note 4); we expect this effect to reduce in the second half of the year.

Good progress in M&A, opportunities and resources for future investment

We have made ten acquisitions in the financial year to date for a maximum total consideration of £108 million. We also completed the disposal of Texecom, for £65 million (see note 5), which demonstrates our disciplined approach to portfolio management.

Cash generation remained good. This, together with Halma's strong financial position, will support continued investment in growth, both organically and by acquisition.

We have a healthy acquisition pipeline and continue to actively manage our portfolio of global businesses to ensure that it is aligned with our purpose of growing a safer, cleaner, healthier future for everyone, every day, and continues to deliver strong growth and returns over the long term.

Half Year Results

The results for the half year ending 30 September 2021 will be released on Thursday 18 November 2021.

 

For further information, please contact:

Halma plc

Andrew Williams, Group Chief Executive +44 (0)1494 721111

Marc Ronchetti, Chief Financial Officer

Charles King, Head of Investor Relations +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP Communications

Andrew Jaques / Rachel Farrington +44 (0)20 3128 8613

A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com

 

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.

Its purpose defines the three broad market areas where it operates:

· Safety: protecting life as populations grow and protecting worker safety.

· Environment: improving food and water quality, and monitoring air pollution.

· Health: meeting rising healthcare demand as growing populations age and lifestyles change.

It employs over 7,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

In January 2021, Halma was named Britain's Most Admired Company by Management Today.

Notes:

1: Adjusted profit before tax is before amortisation and impairment of acquired intangible assets, acquisition items, restructuring costs and profit or loss on disposal of businesses.

2. The guidance given in our Full Year Results, which were released on 10 June 2021, was as follows: "We currently expect to deliver full year low double-digit percentage organic constant currency profit growth (prior to any IAS 38 impact) and a more normal level of return on sales."

3. This Trading Update is based upon unaudited management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

4. Sterling has strengthened in the period relative to many currencies, including the US Dollar and Euro. If current exchange rates continue throughout the rest of the current financial year, the currency translation impact on the Group's results is expected to be negative. Based on exchange rates of Sterling/US Dollar 1.39 and Sterling/Euro 1.17, we would expect approximately a £53 million negative revenue effect and a £12 million negative profit effect, compared to the 2021 financial year, of which approximately two-thirds would occur in the first half of the financial year.

5. We made ten acquisitions and a disposal in the first half of the financial year.

In April and May 2021, we completed six acquisitions (including five bolt-on acquisitions), as previously announced in our Annual Report and Accounts 2021, and as disclosed in note 32 to the Accounts:

· PeriGen, Inc., whose advanced technology protects mothers and their unborn babies by alerting doctors, midwives and nurses to potential problems during childbirth, was acquired for a cash consideration of US$58 million (equivalent to approximately £42 million at the time of announcement) on a cash- and debt-free basis.

· Assets and IP associated with monitored safety valves from FluidSentry Pty for A$0.6m (£0.3m) were added to Fortress Interlocks.

· Argus Security S.R.L. acquired its Italian distributor for €0.5m (£0.4m);

· Anton Industrial Services, Crowcon's UK flue gas analyser distribution partner, was purchased for £1.9m;

· Orca GmbH, a German manufacturer of ultraviolet disinfection systems, joined our UV Group of companies for a maximum consideration of €8.7m (£7.5m);

· RNK, a US-based digital stethoscope company, joined Riester for a consideration of US$2.7m (£1.9m).

In August 2021, we announced that we had completed three acquisitions:

· the Ramtech group of companies, a UK-based supplier of wireless fire systems for temporary sites, for a cash consideration of £15.5 million, on a cash and debt free basis;

· Dancutter A/S, a Danish designer and manufacturer of trenchless pipeline rehabilitation equipment, for a cash consideration of €18 million (equivalent to £15.4 million at the time of announcement), on a cash and debt free basis;

· Sensitron S.r.l., an Italian gas detection company, for a cash consideration of €21 million (equivalent to £17.9 million at the time of announcement), on a cash and debt free basis

In September 2021, we acquired Meditech Kft, a Hungarian manufacturer of ambulatory blood pressure monitors and ECG Holter devices, for a maximum total consideration of €6.0m (approximately £5.1 million6). It will be integrated with our SunTech business.

In August 2021, we announced that we had completed the sale of Texecom, a provider of electronic security systems, for a total cash consideration of £65 million on a cash and debt free basis.

6. At an exchange rate of Sterling:Euro 1.17.

7. A copy of this announcement, together with other information about Halma, may be viewed on its website at www.halma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSELFMFEFSELU
Date   Source Headline
1st May 20247:00 amRNSAcquisition
19th Mar 20243:53 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTrading Update
4th Mar 20247:00 amRNSAcquisition
21st Feb 20244:17 pmRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSDirectorate Change
30th Nov 20235:28 pmRNSPDMR Shareholding
22nd Nov 20234:36 pmRNSDirector Declaration
20th Nov 20237:00 amRNSAcquisition
16th Nov 20237:00 amRNSHalf Year Results
25th Oct 20237:00 amRNSAcquisitions
3rd Oct 202310:50 amRNSDirector/PDMR Shareholding
27th Sep 202312:28 pmRNSHolding(s) in Company
25th Sep 20231:00 pmRNSDirector/PDMR Shareholding
21st Sep 20237:00 amRNSTrading Update
4th Aug 20237:00 amRNSAcquisition
31st Jul 20233:00 pmRNSDirector/PDMR Shareholding
24th Jul 20239:00 amRNSDirectorate Change
20th Jul 20233:51 pmRNSResult of AGM
30th Jun 20239:00 amRNSDirector/PDMR Shareholding
28th Jun 20233:00 pmRNSDirector/PDMR Shareholding
22nd Jun 20233:58 pmRNSAnnual Financial Report
15th Jun 20237:00 amRNSFull Year Results
30th May 20237:11 amRNSDirector Declaration
12th May 20238:00 amRNSCompletion of acquisition
5th May 20237:00 amRNSAcquisition
28th Mar 20237:00 amRNSAcquisition
16th Mar 20237:00 amRNSTrading update
1st Mar 20233:39 pmRNSDirector/PDMR Shareholding
1st Feb 20237:00 amRNSAcquisition
12th Jan 20237:00 amRNS2022 AGM – Voting Results Update Statement
29th Nov 202212:42 pmRNSDirector/PDMR Shareholding
17th Nov 20227:00 amRNSHalf Year Results
11th Nov 20227:00 amRNSHalma appoints new Chief Financial Officer
6th Oct 20227:00 amRNSAcquisition
3rd Oct 20224:38 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSAcquisition
22nd Sep 20227:00 amRNSTrading Statement
28th Jul 20223:01 pmRNSDirector/PDMR Shareholding
21st Jul 20223:33 pmRNSResult of AGM
4th Jul 20223:38 pmRNSDirector/PDMR Shareholding
29th Jun 20229:54 amRNSDirector/PDMR Shareholding
23rd Jun 20225:50 pmRNSAnnual Financial Report
17th Jun 20224:41 pmRNSDirector/PDMR Shareholding
16th Jun 20227:01 amRNSGroup Chief Executive succession
16th Jun 20227:00 amRNSFinal Results
14th Apr 20227:00 amRNSAcquisition
7th Apr 20227:00 amRNSSite Visit
28th Mar 20221:59 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.